News

Stories

See all

Updates: Lilly's Global COVID-19 Response

View Story

Latinx Out Loud: Colleagues Share Their Experiences

View Story

Lilly Global Day of Service Improves Health, Education and Communities

View Story

The Power of Loxo Oncology at Lilly

View Story

From video approved by Jen Scroggins on Sept 14, 2020

The Impact of Osteoarthritis: Seeing the Person Behind the Pain

View Story

How Lilly Is Helping Discounts Reach People With Diabetes in 340B

View Story


Press Releases

See all

Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascu

September 22, 2020

New indication reflects distinct patient population in the REWIND study – people with type 2 diabetes with multiple cardiovascular risks or established cardiovascular disease TORONTO , Sept. 22, 2020 (GLOBE NEWSWIRE) -- On September 11, 2020 , Health Canada approved Trulicity® (dulaglutide) to



Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

September 20, 2020

Tags |  Product

Verzenio in combination with endocrine therapy is the only CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in invasive disease-free survival (IDFS) in early breast cancer   The Phase 3 monarchE trial evaluating the effects of two years of Verzenio treatment added to



CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis

September 18, 2020

Tags |  Product

Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine INDIANAPOLIS , Sept. 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for



Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

September 17, 2020

Tags |  Corporate

Agreement will significantly increase global supply capacity for Lilly's potential COVID-19 treatments INDIANAPOLIS and THOUSAND OAKS, Calif. , Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to